Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]
As you already know, I am very interested and a strong believer in the future of immunologic therapy. I have written extensively about Provenge and last week I told you about a phase I clinical trial of a Vaccine Therapy for men with progressive stage D0 (non-metastatic) prostate cancer. (http://advancedprostatecancer.net/?p=1419). I want to now let [...]
The September issue of The Journal of Nuclear Medicine published a study that shows that positron emission tomography (PET)/computer tomography (CT) scans using the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed. Men who elect to have a radical prostatectomy [...]
The absence of a stromal protein called caveolin-1 appears to be a marker for advanced prostate cancer and for metastasis, researchers from the Kimmel Cancer Center at Jefferson and Harvard Medical School reported in "Cell Cycle." Caveolin-1 has already been shown to be a good biomarker serving as a prognostic factor for breast cancer. The [...]
The authors of a recent study from the Duke Prostate Center and Division of Urology, Department of Surgery, Duke University Medical Center, Durham, N.C. and the Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan reviewed the current salvage methods for treating recurrent local recurrent prostate cancer after primary radiotherapy (RT). They used a [...]